MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics
Authors' conclusion
We believe that MetSCORE may be an insightful tool for early intervention and lifestyle modifications, potentially preventing the aggravation of metabolic syndrome.
Study context
- Population
- Large cohort of donors (37.5% female); Metabolic syndrome (MetS) identified using the WHO criterium37.5% female
- Participants
- 21,323 participants
- Outcome
- Discrimination of MetS (WHO criterium) from general population
Methodological detailsNMR-based metabolomics, large cohort, 41 circulating metabolites and 112 lipoprotein classes and subclasses determined in serum, integrated with urine metabolic profiles
- NMR-based metabolomics
- Large cohort
- 41 circulating metabolites and 112 lipoprotein classes and subclasses determined in serum, integrated with urine metabolic profiles
Performance
As reported in the abstract
| Test or model | AUC |
|---|---|
| MetSCORE | 0.94 (95% CI 0.920-0.952, p < 0.001) |
MetSCORE
AUC0.94 (95% CI 0.920-0.952, p < 0.001)
Further findings
- MetSCORE discriminates intermediate phenotypes, identifying early risk of MetS quantitatively and ranking individuals by risk (general population) or by severity (MetS patients)
Original publication
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics. Cardiovasc Diabetol. Published 24 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →